Wednesday 03 July 2024
Internal Reference Number: FOI_7701
Date Request Received: 23/01/2024 00:00:00
Date Request Replied To: 26/01/2024 00:00:00
This response was sent via: By Email
Request Summary: Treatment with Specified Products
Request Category: Private Individuals
| Question Number 1: Could you please provide answers to the following questions, with regards to treatments with the specified products: in the past 6 months, how many patients were treated with a combination of both Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases: A) Metastatic Melanoma B) Colorectal Cancer C) Any other indications | |
| Answer To Question 1: A) Metastatic Melanoma 0 Patients B) Colorectal Cancer 0 Patients C) Any other indications None | |
| Question Number 2: In the past 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases: A) Metastatic Melanoma B) Adjuvant Melanoma C) BRAF mutated Lung Cancer | |
| Answer To Question 2: A) Metastatic Melanoma 0 Patients B) Adjuvant Melanoma 0 Patients C) BRAF mutated Lung Cancer <5 patients | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
